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Introduction
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) constitutes a group of disorders characterized by autoimmune necrotizing infl ammation of small blood vessels, which leads to systemic organ damage [1] . Th is group of systemic vasculitides includes Wegener's granulomatosis (WG), microscopic polyangiitis (MPA), and Churg-Strauss syndrome (CSS). Th ese disorders are predominantly associated with the presence of circulating ANCAs that are directed against proteins in the cytoplasmic granules of neutrophils. ANCAs with specifi city for proteinase-3 (PR3-ANCA) are associated with WG to a high degree, whereas ANCAs with specifi city for myeloperoxidase (MPO-ANCA) are predominant in MPA and to a lesser degree in CSS [2] . Although it remains unknown how these conditions develop, it has been postulated that ANCA in vivo bind to surface-expressed autoantigens (PR3 or MPO) on primed neutrophils, which enhances neutrophil degranulation and the release of toxic products that cause endothelial damage, ultimately leading to necrotizing vasculitis [2] .
In vivo experimental studies have clearly demonstrated that MPO-ANCAs are pathogenic factors. Xiao and colleagues have shown that immunization of MPOdefi cient mice with mouse MPO results in an MPOdirected immune response, and transfer of splenocytes from these mice into immune-defi cient mice leads to development of pauci-immune necrotizing crescentic glomerulonephritis and systemic necrotizing vasculitis reminiscent of MPA [3] . Further support for the pathogenicity of ANCA comes from a recent study by van Timmeren and coworkers [4] . Th ey observed that adminis tration of anti-MPO antibodies hydrolyzed by the bacterial enzyme endoglycosidase S, which abolishes IgG binding to Fcγ receptors, attenuated both neutrophil infl ux and formation of glomerular crescents in the abovedescribed model of MPO-ANCA-induced glomerulonephritis. An immunopathogenic role for MPO-ANCA has also been strongly suggested by the occurrence of neonatal MPA in a child born to a mother with a history of MPO-ANCA-associated pulmonary renal syndrome [5] .
In contrast to MPO-ANCA, in vivo evidence is still lacking for a direct vasculitic pathogenicity of PR3-ANCA. So far only PR3-induced and PR3-ANCA-induced enhancement of infl ammation has been demonstrated in an animal model [6, 7] . Recent fi ndings by Primo and colleagues suggest that, under certain conditions, anti-PR3 antibodies can be pathogenic in rodents [8] . Th ey showed that adoptive transfer of splenocytes from PR3-immunized mice into NOD-SCID mice resulted in the appearance of circulating anti-PR3 antibodies and crescentic glomerulo nephritis in the recipient mice. However, it is unclear whether glomerulonephritis in recipient mice is mediated by the humoral or the cellular arm of the anti-PR3 response.
Of note, infi ltrating T cells in granulomatous lesions as well as persistent T-cell activation have been reported in AAV patients [9] [10] [11] [12] . Interestingly, T-cell-depleting therapy with anti-CD52 antibodies (alemtuzumab) and
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anti-thymocyte globulin can induce remission in refractory AAV patients [13, 14] . Moreover, the IgG subclass distribution of ANCA, predominantly consisting of IgG 1 and IgG 4 , implies isotype switching of ANCA for which CD4 T-helper cells are required [15] . T-cellmediated immunity is thus thought to contribute to the patho genesis of ANCA-associated vasculitis. In the present review we will summarize the currently available data on the role of T cells in AAV. We shall fi rst discuss current thoughts about the contribution of T cells to tissue injury in AAV. Th e main emphasis will then be on the plasticity of regulatory T cells (T Regs ), their transition into Th 17 cells, and the involvement of Th 17 cells in granuloma formation and disease progression. . CD134 is thought to contribute to T-cell migration and tissue infi ltration through its interaction with OX40L on vascular endothelial cells [42] . Indeed, Wilde and coworkers have shown that CD134-expressing T cells were localized within the infl ammatory lesions of WG patients, supporting our hypothesis on migration of this T-cell subset to infl amed sites [41] .
Involvement of CD4 T cells in AAV
As mentioned, CD4 + T EM display natural killer (NK)-like features such as cytotoxicity [39] . Th ey also mimic NK cells by their surface expression of the NKG2D molecule. NKG2D is an activating C-type lectin-like homodimeric receptor, which diff ers from other NKG2 members as it apparently lacks an antagonist and substitutes for CD28-mediated co-stimulatory signaling in CD28 -T EM [43] . One of the NKG2D ligands is the major histo compatibility complex class-I chain-related molecule A (MICA), which is expressed upon cellular injury and stress on target cells such as fi broblasts and epithelial cells [43] . Proof of concept for NKG2D-mediated tissue destruction was provided by Allez and colleagues [44] , who demonstrated that NKG2D + CD4 + T-cell clones from patients with Crohn's disease kill target cells that express MICA via NKG2D-MICA interaction. Importantly, MICA is upregulated in peritubular endothelium and glomerular epithelial cells in AAV patients during active renal disease [45] . Strikingly, Capraru and colleagues have shown that NKG2D is preferentially expressed on expanded CD28
-CD4 + T cells in the peripheral blood of WG patients [31] . Next, they showed that both NKG2D and MICA are expressed in granulomatous lesions in WG, but not in disease controls. Killing mechanisms via NKG2D-MICA interaction therefore probably contribute to vessel injury and disease progression in AAV patients ( Figure 1 ). Accordingly, selective targeting of NKG2D + CD4
+ T EM or inhibiting MICA expression without impairing other parts of cellular immunity might have value in the treatment of AAV [46] .
Th1/Th2/Th17 paradigm in AAV
Aberrant T-helper cell polarization has been described in AAV. Analysis of soluble markers for T-helper cell subsets in patient sera reveals a predominance of the Th 1 pattern with expression of IFNγ and sCD26 in patients with localized WG and in patients with MPA, whereas a shift towards a Th 2 pattern, with expression of IL-4, IL-5, IL-10, IL-13, sCD23, and sCD30, was observed in active generalized WG and CSS [47, 48] . Th e same results were obtained from analysis of nasal granulomatous lesions in which abundant Th 1-associated markers (IFNγ, sCD26, CCR5) were seen during localized WG, whereas Th 1-associated and Th 2-associated markers (IL-4 and CCR3) are found in generalized WG [20, 49] . Besides the balance between Th 1 and Th 2, a recent breakthrough has revealed that IL-17-secreting T cells (Th 17) are another major pathogenic eff ector subset involved in the induction of infl ammation and autoimmunity [50, 51] . It has been reported that induction of experimental autoimmune encephalomyelitis (EAE) was blocked in mice defi cient in either IL-17 or the Th 17 polarizing cytokine IL-23, whereas mice defi cient in either IFNγ or the Th 1 polarizing cytokine IL-12 show increased susceptibility to EAE [50, 52, 53] . Interestingly, Th 17 cells in EAE infi ltrate the brain prior to the onset of clinical symptoms, whereas Th 1 cells dominate the cellular infi ltrate thereafter when clinical disease develops [54] . It seems that T-cell-mediated disease manifestations are linked to Th 17 cells and not primarily to Th 1 responses.
Th e physiological role of Th 17 cells lies in bacterial defense -for example, against Staphylococcus aureusas shown in experimental pneumonia and the hyper-IgE syndrome [55, 56] . Peptidoglycans as well as superantigens from S. aureus might have an immunomodulatory eff ect on dendritic cells by imprinting of a strong Th 17 polarizing capacity [57] . In addition, S. aureus α-toxin was shown to induce IL-17A secretion in CD4 T cells [58] . Intriguingly, nasal S. aureus co-localization has been reported to be related to relapse and correlates with endonasal activity in WG [59, 60] . Infection with S. aureus might therefore drive a Th 17 response in AAV patients. Indeed, in patients with AAV we observed a skewing towards Th 17 cells following in vitro stimulation of peripheral blood samples [61] . In line with this observation, Ordonez and coworkers have shown that the expanded CD4 + memory T cells in AAV patients are a source of IL-17 [37] . Most importantly, we found a relative increase in autoantigen-specifi c Th 17 cells in ANCA-positive patients in com parison with ANCAnegative patients and controls [61] . Th is observation suggests involvement of Th 17 cells in the process of autoantibody production in AAV. Th ese results were corroborated by Nogueira and colleagues, who reported elevated levels of serum IL-17A and increased autoantigen-specifi c Th 17 cells in AAV patients during disease convalescence compared with healthy controls [62] . In addition, Saito and colleagues observed an increased frequency of circulating Th 17 cells in patients with active CSS compared with in patients with inactive disease and healthy controls [63] .
IL-17 has been reported to promote the release of proinfl ammatory cytokines, which are essential for triggering the expression of PR3 and MPO on the surface of neutrophils (priming of neutrophils), and also to induce CXC chemokine release and expression of adhesion molecules responsible for the recruitment of neutrophils to the site of infl ammation [64] [65] [66] . Indeed, WG granulomata (site of infl ammation) are rich in neutrophils [20] . On the other hand, IL-17 has been shown crucial for the formation of an autoreactive germinal center in autoimmune BXD2 mice [67] . IL-17-producing T cells and B cells expressing the IL-17 receptor have also been reported to localize together in germinal centers [67] . Th is observation suggests that IL-17 not only induces tissue infl ammation but also could function on B cells to promote the germinal center reaction. Th e lymphocyte clusters in granuloma struc tures can resemble germinal center-like structures that might be induced by IL-17 and may provide a place for ANCA production. IL-17 thus seems to be an important player in disease development in AAV and in early granuloma formation in WG, whereas Th 1 and Th 2 cells might prevail in later stages [20, 49] . Of note, Th 17 cells have not so far been demonstrated at infl amed sites in AAV.
Disturbance in the frequency and/or function of regulatory T cells in AAV
Natural T Regs , a subset of thymus-derived CD4 + T cells expressing a high level of IL-2Rα (CD25) and a unique transcription factor FoxP3, have been shown critical for preventing autoimmune responses. Defects in T Reg function or reduced numbers of T Regs have been documented in several autoimmune diseases [68] . Indeed, we found that the suppressive function of T Regs was defective in WG patients as compared with healthy controls [69] . In this group of patients, however, we observed a signifi cant increase of memory FoxP3 + CD25 High T Regs . In line with these fi ndings, Klapa and colleagues demonstrated an increased number of FoxP3 + T cells as well as phenotypical and functional alterations of T Regs in WG patients [70] . Th ey reported an increased number of interferon receptor I-positive T Regs in the peripheral blood of WG patients [70] . In addition, they showed that IFNα exaggerates functional T Reg impair ment ex vivo in response to the autoantigen PR3 [70] . T Regs in WG patients might thus display functional anergy in the context of an infl ammatory cytokine milieu.
Altered T Reg function in WG patients has also been reported by Morgan and coworkers [71] . Th ey observed that T Regs from healthy controls and from ANCA-negative patients were able to suppress T-cell proliferation to PR3, whereas T Regs from ANCA-positive patients failed to suppress this autoimmune response [71] . Dysfunction of T Regs is thus believed to play a role in the development of WG. In contrast, T Reg function in MPA patients was comparable with that in healthy controls, but FoxP3 levels were diminished in MPA patients [72] . MPA seems to be associated with a numerical defi ciency rather than a functional defi ciency of T Regs . More over, studies in CSS patients showed that both patients and controls have a similar number of CD25 + CD4 + T cells with an equal percentage of FoxP3-expressing cells. However, the suppressive function of T Regs in CSS patients still needs to be investigated [63, 73] .
Plasticity of T Regs in AAV: conversion towards Th17 eff ector cells within an infl ammatory milieu
A reciprocal relationship in the development of T Regs and Th 17 cells has recently been described. Th is may underlie the propensity of T Regs to convert to Th 17 cells in the context of proinfl ammatory stimuli, a phenomenon that has only recently been recognized [74] [75] [76] . Under neutral conditions in vitro, transforming growth factor beta can shift the balance towards functional FoxP3 + T Regswhereas in the context of an infl ammatory cytokine milieu (IL-1β, IL-2, IL-6, IL-15, IL-21, IL-23), functional T Regs convert towards IL-17-producing, nonfunctional T Regs . Th e rela tively novel notion of T-cell lineage plasticity is of interest in relation to many papers describing nonfunctional T Regs in several autoimmune conditions, including AAV. Our hypothesis is that these nonfunctional FoxP3 + T cells have lost their suppressive function due to co-expression of a second Th 17 lineage-associated transcription factor RORγt that interferes with Foxp3 activity [77] . Recently, diff erent isoforms of FoxP3 have been investigated in human T Regs that have been shown to impact T Reg function and lineage commitment. More specifi cally, the full-length isoform (FoxP3fl ) -but not the isoform lacking exon 2 (FoxP3Δ2) -interacts with RoRγt and inhibits the expression of genes that defi ne Th 17 cells [78] [79] [80] . Based on the aforementioned data, the putative nonfunctional T Regs described in AAV may lack their suppressive function due to upregulation of the FoxP3Δ2 isoform that fails to inhibit RORγt-mediated IL-17A mRNA trans cription. Upon stimulation in an infl amed context, these cells convert into IL-17-producing eff ector T cells.
Evidence from several groups of investigators, including our own, support this hypothesis of conversion of T Regs into eff ector IL-17-secreting cells in AAV. As mentioned before, we found a signifi cant increase in the percentage of FoxP3 + CD25 High T Regs with a defective regulatory function in AAV patients in remission as compared with healthy controls. Furthermore, we demon strated a concurrent increase in the percentage of Th 17 cells upon in vitro stimulation of peripheral blood samples from AAV patients. Consistent with this, patients with AAV had signifi cantly higher serum levels of IL-17 compared with healthy controls [62] . Importantly, increased serum levels of IL-17 in AAV patients correlated signifi cantly with increased levels of the cytokines that are involved in the conversion of T Regs into Th 17 cells; that is, IL-1β, IL-23 and IL-6 [62] . In addition, patients with active CSS showed an increased frequency of Th 17 cells with a decrease in the frequency of IL-10-producing T Regs , whereas an inverse result was observed in CSS patients with inactive disease [63] . Th e aforementioned data appear to support a link between the conversion of T Regs into Th 17 cells and disease activity in AAV (Figure 1) .
Therapeutic targets in patients with AAV
Because Th 17 cells contribute to infl ammation and granuloma formation, this T-cell subset could be a novel therapeutic target for AAV. Depletion of Th 17 cells by targeting specifi c surface proteins may be diffi cult as Th 17 cells share many surface markers with other T-cell subsets. A therapeutic approach targeting its cytokine (that is, IL-17) would therefore be more feasible. Indeed, neutralizing IL-17 by anti-IL-17 antibody or by soluble IL-17 receptors reduces infl ammation and bone erosion in various animal arthritis models [81] . Interestingly, humanized anti-IL-17 mAbs -including AIN457 and LY2439821, which neutralize the biologic activity of IL-17 -are in clinical trials. Th ese biologicals have been shown to induce clinically relevant responses in patients with psoriasis, rheumatoid arthritis, and non-infectious uveitis, compared with placebo without safety issues [82, 83] . Neutralization of IL-17 could therefore represent a novel therapeutic approach for patients with AAV.
On the other hand, CD4 + T EM -supposed to act as a key trigger of disease expression and relapse in AAVmay also serve as a therapeutic target. Selective targeting of CD4 + T EM without impairing other parts of the humoral and cellular immune system could be a major step forward in the treatment of AAV. NKG2D blockade by anti-NKG2D antibodies has been reported to prevent autoimmune diabetes in NOD mice [84] . Blocking of NKG2D could be a new strategy in the treatment of AAV. Other studies have revealed that targeting of the voltagegated Kv1.3 channel, which is highly expressed on activated CD4 + T EM , provides a specifi c immunomodulatory approach [85, 86] . Blockade of the Kv1.3 channel by ShK(L5) amide eff ectively prevented autoimmune disease in the EAE model of multiple sclerosis and suppressed delayed-type hypersensitivity in rats [85, 86] . Th e selective targeting of CD4 + T EM using ShK(L5) amide and/or blocking the NKG2D-MICA interaction by anti-NKG2D antibodies may therefore hold therapeutic promise for AAV. 
Conclusion

